Novo Nordisk’s production facility in Algeria will begin exporting insulin pens to several African countries starting this September, according to a statement released on Sunday.
Hamza Benharkat, the general manager of Novo Nordisk Algeria, stated that the company aims to maximize the use of its manufacturing facilities to ensure a constant supply of modern medicines for Algerian patients. He reaffirmed the company’s commitment to optimizing its production capabilities.
Novo Nordisk Algeria, which has two factories—one in Tizi Ouzou and the other in Boufarik (Blida)—successfully completed its first export of insulin pens to Saudi Arabia at the end of April. This initial shipment, carried out in three phases, involved 2.5 million insulin pens and generated a revenue of 11 million euros. Additionally, the Tizi Ouzou factory, operational since 2006, also exported its first batch of metformin to Libya in November 2023. This facility, specializing in the production of dry forms of diabetes medications, meets 50% of the national demand for metformin.
The launch of insulin pen exports to Africa is part of a broader strategy by Novo Nordisk to strengthen its presence in the African market and address the growing need for diabetes care. This initiative is also seen as a way to improve access to treatment for patients in neighboring countries.
Novo Nordisk Algeria’s commitment to expanding its production capabilities while venturing into exports highlights its key role in supplying modern medicines, both for the local market and across the African continent. These efforts aim not only to enhance the health of Algerian patients but also to solidify Algeria’s position as a pharmaceutical manufacturing hub in Africa. R.N
+ There are no comments
Add yours